3,0
21 dic 2016
Ex dipendente, più di un anno
Raleigh, NC
Consiglia
Gradimento del CEO
Pronostico commerciale
Vantaggi
Good friendly R&D colleagues at the RTP site, most of which were let go in 2015. Some "DPUs" were bringing some interesting programs to the pipeline.
Svantaggi
Huge R&D organization with lots of layers, massive bureaucracy, all process driven with zero thinking or creativity, brutal inter-site competition. GSK now knows that it cannot compete as an R&D organization, it's unable to discover and develop new drugs, new CEO coming in 2017 to try to stop downward spiral, good luck.